Medical experts underscore disparities in diabetes treatment access, stressing the impact of insurance plans on treatment decisions, which can hinder patients and providers, especially when considering newer medications like GLP-1 agonists.
Enhancing Cardiovascular Health in End-Stage Kidney Disease, with Maya N. Clark-Cutaia, PhD, RN
Diabetes Dialogue: 2024 ACP Type 2 Diabetes Recommendations
New 4-Year Extension Trial Results Announced for Deucravacitinib Treatment of Psoriasis
Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies
Oral Liposomal Iron Helps Correct Iron Deficiency in Non-Dialysis CKD
Evinacumab Reduces Lipids, Cholesterol in Hypercholsterolemia and Hypertriglyceridemia